Showing results (21-30 of 40) with videos related to
Sort By:
Pageof 4
Biochemical and Biophysical Research Communications|May 18, 2011
An ABCA1 truncation shows no dominant negative effect in a familial hypoalphalipoproteinemia pedigree with three ABCA1 mutationsBrie Sorrenson, Rachel J Suetani, Vivienne M Bickley, et al.Cardiovascular Drugs and Therapy|August 5, 2009
Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteineMichael Lever, Peter M George, Sandy Slow, et al.Journal of Pediatric Endocrinology & Metabolism : JPEM|May 17, 2002
Incidence of type 1 diabetes mellitus diagnosed before age 20 years in Canterbury, New Zealand over the last 30 yearsJinny A Willis, Russell S Scott, Brian A Darlow, et al.American Journal of Hypertension|November 25, 2011
A randomized, double-blind, placebo-controlled crossover study of coenzyme Q10 therapy in hypertensive patients with the metabolic syndromeJoanna M Young, Christopher M Florkowski, Sarah L Molyneux, et al.Clinical Cardiology|December 3, 2003
Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroupsMichael H Davidson, Leiv Ose, Jiri Frohlich, et al.Diabetes Research and Clinical Practice|March 13, 2024
Not enough known about fenofibrate's kidney effects in people with Type 2 diabetesAlicia J Jenkins, Rachel L O'Connell, Andrzej S Januszewski, et al.Diabetes Research and Clinical Practice|March 13, 2025
Relationship of haptoglobin phenotype and levels with sight-threatening diabetic retinopathy in type 2 diabetes: A Fenofibrate Intervention and Event Lowering in diabetes (FIELD) substudyKwok Leung Ong, Andrzej S Januszewski, Habib Francis, et al.Diabetes, Obesity & Metabolism|April 4, 2020
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD studyJacob Y Cao, Boris Waldman, Rachel O'Connell, et al.Diabetologia|June 10, 2015
Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes studyKwok-Leung Ong, Andrzej S Januszewski, Rachel O'Connell, et al.European Journal of Preventive Cardiology|September 19, 2025
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-studyKwok Leung Ong, Andrzej S Januszewski, Habib Francis, et al.Pageof 4